Immunocore Financial Statements From 2010 to 2025

IMCR Stock  USD 28.38  1.66  5.53%   
Immunocore Holdings financial statements provide useful quarterly and yearly information to potential Immunocore Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunocore Holdings financial statements helps investors assess Immunocore Holdings' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immunocore Holdings' valuation are summarized below:
Gross Profit
299.7 M
Profit Margin
(0.16)
Market Capitalization
1.5 B
Enterprise Value Revenue
3.5997
Revenue
310.2 M
There are over one hundred nineteen available fundamental trends for Immunocore Holdings, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm Immunocore Holdings' regular fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to grow to about 3.2 B. Also, Enterprise Value is likely to grow to about 2.8 B

Immunocore Holdings Total Revenue

325.71 Million

Check Immunocore Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunocore Holdings' main balance sheet or income statement drivers, such as Interest Expense of 19.8 M, Other Operating Expenses of 399.7 M or Net Interest Income of 7.1 M, as well as many indicators such as Price To Sales Ratio of 4.52, Dividend Yield of 0.0 or PTB Ratio of 3.88. Immunocore financial statements analysis is a perfect complement when working with Immunocore Holdings Valuation or Volatility modules.
  
Check out the analysis of Immunocore Holdings Correlation against competitors.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Holdings Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities187.5 M178.6 M48.7 M
Slightly volatile
Total Current Liabilities222.8 M212.2 M68.1 M
Slightly volatile
Other Liabilities5.1 M5.3 M21.4 M
Slightly volatile
Net Tangible Assets336.1 M320.1 M179.3 M
Slightly volatile
Accounts Payable13.3 M25.1 M8.8 M
Slightly volatile
Other Assets7.5 M10.4 M6.6 M
Slightly volatile
Net Receivables37.1 M63 M25.4 M
Slightly volatile
Other Stockholder Equity1.2 B1.2 B360.2 M
Slightly volatile
Total Current Assets976.4 M929.9 M313.7 M
Slightly volatile
Property Plant Equipment33.1 M36.4 M23.6 M
Slightly volatile
Other Current Assets24.2 M41 M12.7 M
Slightly volatile
Total Assets1.1 BB346.8 M
Slightly volatile
Short and Long Term Debt Total63 M41.7 M38.4 M
Slightly volatile
Total Stockholder Equity205.3 M360.7 M122.8 M
Slightly volatile
Property Plant And Equipment Net41.8 M47.7 M29.7 M
Slightly volatile
Cash282.4 M455.7 M192.1 M
Slightly volatile
Non Current Assets Total56.7 M79.6 M38.4 M
Slightly volatile
Long Term Debt410.6 M391 M73.1 M
Slightly volatile
Cash And Short Term Investments861.4 M820.4 M251.1 M
Slightly volatile
Common Stock Shares Outstanding43.2 M50 M33.5 M
Slightly volatile
Liabilities And Stockholders Equity1.1 BB346.8 M
Slightly volatile
Non Current Liabilities Total458.4 M436.6 M131.7 M
Slightly volatile
Total Liabilities681.2 M648.8 M213.2 M
Slightly volatile
Net Invested Capital789.3 M751.7 M205.6 M
Slightly volatile
Property Plant And Equipment Gross58.8 M103.1 M37.5 M
Slightly volatile
Net Working Capital753.6 M717.7 M225.2 M
Slightly volatile
Intangible Assets351369179 K
Slightly volatile
Current Deferred Revenue5.2 M5.4 M31.2 M
Slightly volatile
Short and Long Term Debt15.3 M17.2 M18.8 M
Slightly volatile
Common Stock Total Equity800900981
Slightly volatile
Common Stock100.3 K155.2 K36.7 K
Slightly volatile
Good Will327.7 K368.6 K401.9 K
Slightly volatile

Immunocore Holdings Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses399.7 M380.7 M113.9 M
Slightly volatile
Interest Income26.9 M25.6 M4.9 M
Slightly volatile
Depreciation And Amortization5.8 M3.7 M6.7 M
Slightly volatile
Selling General Administrative96.9 M155.8 M61.7 M
Slightly volatile
Selling And Marketing Expenses101 M115 M91.8 M
Slightly volatile
Total Revenue325.7 M310.2 M82.8 M
Slightly volatile
Research Development126.7 M222.2 M100.1 M
Slightly volatile
Total Operating Expenses221.9 M377.9 M161 M
Slightly volatile
Reconciled Depreciation5.4 M4.2 M6.7 M
Slightly volatile
Cost Of Revenue2.6 M2.7 M72.2 M
Slightly volatile

Immunocore Holdings Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
DepreciationM4.2 M5.2 M
Slightly volatile
Total Cash From Financing Activities361.1 M343.9 M92.3 M
Slightly volatile
End Period Cash Flow279.4 M455.7 M180.7 M
Slightly volatile
Stock Based Compensation25.2 M34.2 M11.9 M
Slightly volatile
Begin Period Cash Flow249.7 M442.6 M156.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.524.754131.1291
Slightly volatile
PTB Ratio3.884.088416.0307
Pretty Stable
Days Sales Outstanding70.4374.1397443
Slightly volatile
Book Value Per Share7.587.21563.3379
Slightly volatile
Average Payables8.5 M11.1 M9.5 M
Slightly volatile
Stock Based Compensation To Revenue0.10.11020.191
Slightly volatile
Capex To Depreciation1.291.23050.6189
Slightly volatile
PB Ratio3.884.088416.0307
Pretty Stable
EV To Sales3.253.419427.6707
Slightly volatile
Payables Turnover0.10.10885.0373
Slightly volatile
Sales General And Administrative To Revenue1.63.01.9272
Slightly volatile
Research And Ddevelopement To Revenue0.680.71612.7258
Slightly volatile
Capex To Revenue0.01580.01670.1076
Slightly volatile
Cash Per Share17.2316.41056.4595
Slightly volatile
Days Payables Outstanding2.9 K3.4 K1.5 K
Slightly volatile
Intangibles To Total Assets0.0010.00110.0208
Pretty Stable
Net Debt To EBITDA6.175.87592.4133
Slightly volatile
Current Ratio2.854.38243.4597
Pretty Stable
Tangible Book Value Per Share7.587.21563.2844
Slightly volatile
Receivables Turnover7.524.92313.7186
Slightly volatile
Shareholders Equity Per Share7.587.21563.3379
Slightly volatile
Debt To Equity0.110.11560.5783
Very volatile
Capex Per Share0.110.10350.1135
Slightly volatile
Revenue Per Share6.526.20511.9549
Slightly volatile
Interest Debt Per Share1.311.21131.1619
Slightly volatile
Debt To Assets0.03930.04130.1315
Pretty Stable
Price Book Value Ratio3.884.088416.0307
Pretty Stable
Days Of Payables Outstanding2.9 K3.4 K1.5 K
Slightly volatile
Ebt Per Ebit1.090.75130.9744
Slightly volatile
Effective Tax Rate0.03320.03490.1444
Slightly volatile
Company Equity Multiplier4.292.79863.7063
Very volatile
Long Term Debt To Capitalization0.09520.10020.2408
Slightly volatile
Total Debt To Capitalization0.09850.10360.2779
Very volatile
Debt Equity Ratio0.110.11560.5783
Very volatile
Quick Ratio3.04.35673.6297
Pretty Stable
Net Income Per E B T0.710.96510.8396
Slightly volatile
Cash Ratio2.172.14782.5745
Pretty Stable
Days Of Sales Outstanding70.4374.1397443
Slightly volatile
Price To Book Ratio3.884.088416.0307
Pretty Stable
Fixed Asset Turnover6.826.49842.2514
Slightly volatile
Debt Ratio0.03930.04130.1315
Pretty Stable
Price Sales Ratio4.524.754131.1291
Slightly volatile
Asset Turnover0.180.30730.1688
Slightly volatile
Price Fair Value3.884.088416.0307
Pretty Stable

Immunocore Holdings Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 BB1.4 B
Slightly volatile
Enterprise Value2.8 B2.7 B1.3 B
Slightly volatile

Immunocore Fundamental Market Drivers

Cash And Short Term Investments820.4 M

Immunocore Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunocore Holdings Financial Statements

Immunocore Holdings shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunocore Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in Immunocore Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunocore Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.4 M5.2 M
Total Revenue310.2 M325.7 M
Cost Of Revenue2.7 M2.6 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 3.00  1.60 
Research And Ddevelopement To Revenue 0.72  0.68 
Capex To Revenue 0.02  0.02 
Revenue Per Share 6.21  6.52 
Ebit Per Revenue(0.23)(0.24)

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving together with Immunocore Stock

  0.61A Agilent TechnologiesPairCorr

Moving against Immunocore Stock

  0.37DRUG Bright Minds BiosciencesPairCorr
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.